

Magdalena KuÅma-Kozakiewicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7025636/publications.pdf>

Version: 2024-02-01

37
papers

587
citations

759055

12
h-index

677027

22
g-index

37
all docs

37
docs citations

37
times ranked

953
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 404-413.	1.1	84
2	ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 293.	1.1	54
3	SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. <i>Scientific Reports</i> , 2022, 12, 103.	1.6	48
4	An observational study on quality of life and preferences to sustain life in locked-in state. <i>Neurology</i> , 2019, 93, e938-e945.	1.5	41
5	Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. <i>Journal of Neurology</i> , 2018, 265, 1600-1606.	1.8	34
6	Spreading in ALS: The relative impact of upper and lower motor neuron involvement. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1181-1192.	1.7	34
7	Dynactin Deficiency in the CNS of Humans with Sporadic ALS and Mice with Genetically Determined Motor Neuron Degeneration. <i>Neurochemical Research</i> , 2013, 38, 2463-2473.	1.6	31
8	Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. <i>Journal of Neurology</i> , 2020, 267, 2130-2141.	1.8	23
9	New therapeutic targets for amyotrophic lateral sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 127-143.	1.5	18
10	Influence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population. , 2019, 10, 205.		18
11	International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 505-510.	1.1	17
12	Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. <i>Neurological Sciences</i> , 2020, 41, 1115-1124.	0.9	15
13	Validation of qPCR reference genes in lymphocytes from patients with amyotrophic lateral sclerosis. <i>PLoS ONE</i> , 2017, 12, e0174317.	1.1	14
14	Intraspinal Transplantation of the Adipose Tissue-Derived Regenerative Cells in Amyotrophic Lateral Sclerosis in Accordance with the Current Expertsâ€™ Recommendations: Choosing Optimal Monitoring Tools. <i>Stem Cells International</i> , 2018, 2018, 1-16.	1.2	13
15	Existential decision-making in a fatal progressive disease: how much do legal and medical frameworks matter?. <i>BMC Palliative Care</i> , 2017, 16, 80.	0.8	12
16	Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?. <i>Frontiers in Neurology</i> , 2021, 12, 761355.	1.1	12
17	Kinesin Expression in the Central Nervous System of Humans and Transgenic hSOD1G93AMice with Amyotrophic Lateral Sclerosis. <i>Neurodegenerative Diseases</i> , 2013, 12, 71-80.	0.8	11
18	Cardiovascular comorbidities in amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2021, 421, 117292.	0.3	10

#	ARTICLE	IF	CITATIONS
19	Gastrostomy and mechanical ventilation in amyotrophic lateral sclerosis: how best to support the decision-making process?. <i>Neurologia i Neurochirurgia Polska</i> , 2020, 54, 366-377.	0.6	10
20	Mice with Mutation in Dynein Heavy Chain 1 Do Not Share the Same Tau Expression Pattern with Mice with SOD1-Related Motor Neuron Disease. <i>Neurochemical Research</i> , 2011, 36, 978-985.	1.6	9
21	Alteration of Motor Protein Expression Involved in Bidirectional Transport in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. <i>Neurodegenerative Diseases</i> , 2016, 16, 235-244.	0.8	9
22	SMN1 gene duplications are more frequent in patients with progressive muscular atrophy. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 457-462.	1.1	8
23	Dyslipidemia in patients with amyotrophic lateral sclerosis – a case control retrospective study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 195-205.	1.1	8
24	Recurrent K3E mutation in Cu/Zn superoxide dismutase gene associated with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 608-614.	1.1	7
25	Motor neuron disease beginning with frontotemporal dementia: clinical features and progression. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 508-516.	1.1	7
26	Putative founder effect in the Polish, Iranian and United States populations for the L144S <i>SOD1</i> mutation associated with slowly uniform phenotype of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 80-85.	1.1	6
27	Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. <i>Neurologia i Neurochirurgia Polska</i> , 2019, 53, 99-112.	0.6	6
28	Recurrent G41S mutation in Cu/Zn superoxide dismutase gene (<i>SOD1</i>) causing familial amyotrophic lateral sclerosis in a large Polish family. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 132-136.	2.3	5
29	Healthcare provision in amyotrophic lateral sclerosis: procedures, queries and pitfalls in Germany and Poland. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 193-202.	1.1	4
30	Edaravone in the treatment of amyotrophic lateral sclerosis. <i>Neurologia i Neurochirurgia Polska</i> , 2018, 52, 124-128.	0.6	3
31	Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based case-control study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 671-672.	0.9	3
32	Peripheral neuropathy in ALS: phenotype association. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1133-1134.	0.9	3
33	Changes in kinesin expression in the CNS of mice with dynein heavy chain 1 mutation. <i>Acta Biochimica Polonica</i> , 2013, 60, 51-5.	0.3	3
34	Clinical trials in pediatric ALS: a TRICALS feasibility study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 481-488.	1.1	3
35	Caregivers' divergent perspectives on patients' well-being and attitudes towards hastened death in Germany, Poland and Sweden. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 252-262.	1.1	2
36	Physical activity in patients with amyotrophic lateral sclerosis: Prevalence, patients' perspectives and relation to the motor performance. <i>NeuroRehabilitation</i> , 2022, 50, 433-443.	0.5	2

#	ARTICLE	IF	CITATIONS
37	ALS and fertility: does ALS affect number of children patients have?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 94-100.	1.1	0